Sorrento Therapeutics, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported revenue was USD 52.9 million compared to USD 39.99 million a year ago. Net loss was USD 428.33 million compared to USD 298.46 million a year ago.

Basic loss per share from continuing operations was USD 1.45 compared to USD 1.3 a year ago. Diluted loss per share from continuing operations was USD 1.45 compared to USD 1.3 a year ago.